James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA

Activity Chair

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA

  • Lipidology & Cardiovascular Disease Prevention
  • Clinical Assistant Professor of Medicine
  • NYU Medical School & NYU Center for CV Prevention
  • Director, Bellevue Hospital Lipid Clinic
  • New York, NY

Saturday, December 2, 2017

The Westin New York at Times Square
Gershwin Ballroom, 4th Floor
270 West 43rd Street
New York, NY

  • 7:30 am – 8:00 am
  • Registration and Breakfast
  • 8:00 am – 12:00 pm
  • CME-certified Activity

Program Overview

Nearly one-third of adults in the United States have an elevated low-density lipoprotein cholesterol (LDL-C), which is a major risk factor for cardiovascular disease and stroke. Frontline intervention for these patients is diet and exercise, as well as statin therapy. Although this approach is beneficial to many patients, nearly 30% of patients fail to meet their treatment goals on statin therapy and many cannot tolerate intensification of therapy with higher dosing. For these patients and for those with severely elevated LDL-C levels, physicians must consider the use of non-statin therapies to achieve treatment goals. Clinical data regarding the long-term safety and efficacy of non-statin LDL-C–lowering agents continue to emerge, resulting in frequent updates to clinical guidelines. This educational initiative will address the most recent clinical updates regarding the use of non-statin therapies, as well as provide expert advice regarding their utilization, to improve the management of patients with elevated LDL-C and reduce cardiovascular risk.

Copyright © Vindico Medical Education | Privacy Policy
856.994.9400 | 6900 Grove Road, Building 100 | Thorofare, New Jersey 08086
A Wyanoke Group Company